肝細胞がん（HCC）治療薬の世界市場レポート 2024年

肝細胞がん（HCC）治療薬の市場規模は近年力強く成長しています。2023年の10億7,000万米ドルから2024年には11億7,000万米ドルへと、CAGR9.5％で拡大します。過去に見られた拡大は、疾患罹患率の増加、がん研究の進歩、世界のヘルスケアインフラの改善、新しい治療法に対する規制当局の承認、意識向上と早期診断に重点を置いた取り組みなどの要因によるものです。

肝細胞がん（HCC）治療薬市場の成長は、慢性B型肝炎（HBV）およびC型肝炎（HCV）感染に関連した肝臓の炎症状態である肝炎の有病率の増加によってさらに促進されます。慢性肝炎感染はしばしば肝細胞がんの前駆症状である肝硬変につながるため、肝細胞がんに対処する薬剤の重要性が強調されています。2022年4月現在、欧州疾病予防管理センターは、英国、米国、イスラエル、日本を含む様々な国で、注目すべき数の肝炎患者が発生していることを報告しています。この肝炎の有病率の上昇は、肝細胞がん（HCC）治療薬市場の成長を促進する重要な要因です。

2023年の肝細胞がん（HCC）治療薬市場では北米が最大地域でした。肝細胞がん（HCC）治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 市場促進要因・市場抑制要因
  • 市場促進要因
  • 市場抑制要因
• 市場規模と成長実績、2018～2023年
• 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の肝細胞がん（HCC）治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ブラキセラピー
• 化学療法
• 世界の肝細胞がん（HCC）治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• PD-1/PD-L1阻害剤
• チロシンキナーゼ阻害剤
• 世界の肝細胞がん（HCC）治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• がんリハビリテーションセンター
• 外来手術センター

第7章 地域および国の分析

• 世界の肝細胞がん（HCC）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の肝細胞がん（HCC）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肝細胞がん（HCC）治療薬市場の競合情勢
• 肝細胞がん（HCC）治療薬市場の企業プロファイル
  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Hepatocellular Carcinoma Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatocellular carcinoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatocellular carcinoma drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hepatocellular carcinoma drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Brachytherapy; Chemotherapy
• 2) By Drug Class: PD-1/PD-L1 Inhibitors; Tyrosine Kinase Inhibitors
• 3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers
• Companies Mentioned: AbbVie Inc.; Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hepatocellular carcinoma drugs are medications designed for the treatment of primary liver cancer originating from hepatocytes, the primary type of liver cells. Hepatocellular carcinoma often develops in the context of chronic liver diseases, including chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), or liver cirrhosis.

The main types of hepatocellular carcinoma drugs include brachytherapy and chemotherapy. Brachytherapy is a form of radiation therapy employed in cancer treatment, involving the precise placement of radioactive sources directly into or near the tumor site. Radioactive sources used in brachytherapy for hepatocellular carcinoma include iodine-125 and iridium-192. The various drug classes of hepatocellular carcinoma drugs encompass PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors, utilized in settings such as hospitals, clinics, cancer rehabilitation centers, and ambulatory surgical centers.

The hepatocellular carcinoma drugs market research report is one of a series of new reports from The Business Research Company that provides hepatocellular carcinoma drugs market statistics, including hepatocellular carcinoma drugs industry global market size, regional shares, competitors with a hepatocellular carcinoma drugs market share, detailed hepatocellular carcinoma drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatocellular carcinoma drugs industry. This hepatocellular carcinoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The expansion observed in the historical period can be attributed to factors such as increased disease incidence, advancements in cancer research, improvements in global healthcare infrastructure, regulatory approvals for new treatments, and initiatives focused on awareness and early diagnosis.

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be attributed to advancements in targeted therapies, the increasing geriatric population, trends in healthcare personalization, and the global expansion of treatment access. Key trends expected in the forecast period encompass access to innovative therapies, a focus on patient-centric care, advancements in regulatory measures, strategies to mitigate drug resistance, and collaborative research initiatives in the field of hepatocellular carcinoma drugs.

The hepatocellular carcinoma drug market is expected to witness substantial growth in the coming years due to the increasing incidence of hepatocellular carcinoma (HCC), the most common form of liver cancer. HCC originates in hepatocyte cells, the main type of liver cells, and is often associated with hepatitis B or C infections and cirrhosis. The rising occurrence of HCC is driving the demand for effective drugs to treat the disease. According to a 2023 report by the American Cancer Society, the estimated new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, highlighting the need for advancements in hepatocellular carcinoma drugs.

The growth of the hepatocellular carcinoma drugs market is further propelled by the increasing prevalence of hepatitis, an inflammatory condition of the liver linked to chronic hepatitis B (HBV) and hepatitis C (HCV) infections. Chronic hepatitis infections often lead to liver cirrhosis, a precursor to HCC, emphasizing the importance of drugs addressing hepatocellular carcinoma. As of April 2022, the European Centre for Disease Prevention and Control reported a notable number of hepatitis cases in various countries, including the UK, the US, Israel, and Japan. This escalating prevalence of hepatitis is a significant factor driving the growth of the hepatocellular carcinoma drugs market.

Major companies in the market are focusing on developing laboratory-produced molecules, particularly monoclonal antibodies (mAb). Monoclonal antibodies are engineered to mimic the immune system's ability to combat pathogens. AstraZeneca's FDA approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for hepatocellular carcinoma treatment is a notable example of such developments. Imfinzi, a human monoclonal antibody targeting PD-L1, and Imjudo, targeting CTLA-4, work synergistically to enhance the immune response against cancer cells.

Leading companies in the hepatocellular carcinoma drugs market are actively creating innovative products, including liver cancer medications, to cater to larger customer bases, boost sales, and enhance overall revenue. Drugs for liver cancer encompass a diverse range of pharmaceutical interventions aimed at treating and managing the disease. As an example, in October 2022, Eli Lilly and Company, a pharmaceutical firm based in the United States, announced the approval of Cyramza (ramucirumab) by the National Medical Products Administration (NMPA) for the treatment of hepatocellular carcinoma in China. Cyramza is the first novel medicine to receive approval following a specific evaluation in a biomarker-enriched population of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) levels exceeding 400 ng/ml. The study results in Chinese patients demonstrated a consistent efficacy and safety profile comparable to the global population. This approval is expected to positively impact the clinical approach to liver cancer in China by introducing a new and effective treatment option for advanced HCC among Chinese patients.

In August 2023, Novartis AG, a pharmaceutical company based in Switzerland, completed the acquisition of Chinook Therapeutics Inc. for a deal valued at $3.2 billion. Through this strategic acquisition, Novartis aims to leverage the combined resources and expertise to advance the development of promising treatments for individuals with rare and severe chronic kidney diseases. The integration of the Chinook team is anticipated to bolster Novartis in expanding its portfolio related to renal conditions and contribute to its ongoing commitment to redefine medicine. Chinook Therapeutics Inc., headquartered in the United States, specializes in developing treatments for rare and severe chronic kidney disorders, including hepatocellular carcinoma (HCC).

Major companies operating in the hepatocellular carcinoma drugs market report are AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline, Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., TTY Biopharm Company Limited, Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

North America was the largest region in the hepatocellular carcinoma drug market in 2023. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatocellular carcinoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hepatocellular carcinoma drug market consists of revenues earned by entities by providing surgery, radiofrequency ablation, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatocellular carcinoma drug market also includes sales of cabozantinib, ramucirumab and pembrolizumab drugs used for the treatment of hepatocellular carcinoma drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hepatocellular Carcinoma Drugs Market Characteristics

3. Hepatocellular Carcinoma Drugs Market Trends And Strategies

4. Hepatocellular Carcinoma Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Hepatocellular Carcinoma Drugs Market Size and Growth

• 5.1. Global Hepatocellular Carcinoma Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Hepatocellular Carcinoma Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Hepatocellular Carcinoma Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hepatocellular Carcinoma Drugs Market Segmentation

• 6.1. Global Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Brachytherapy
• Chemotherapy
• 6.2. Global Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• PD-1/PD-L1 Inhibitors
• Tyrosine Kinase Inhibitors
• 6.3. Global Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Cancer Rehabilitation Centers
• Ambulatory Surgical Centers

7. Hepatocellular Carcinoma Drugs Market Regional And Country Analysis

• 7.1. Global Hepatocellular Carcinoma Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Hepatocellular Carcinoma Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hepatocellular Carcinoma Drugs Market

• 8.1. Asia-Pacific Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hepatocellular Carcinoma Drugs Market

• 9.1. China Hepatocellular Carcinoma Drugs Market Overview
• 9.2. China Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hepatocellular Carcinoma Drugs Market

• 10.1. India Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hepatocellular Carcinoma Drugs Market

• 11.1. Japan Hepatocellular Carcinoma Drugs Market Overview
• 11.2. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hepatocellular Carcinoma Drugs Market

• 12.1. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hepatocellular Carcinoma Drugs Market

• 13.1. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hepatocellular Carcinoma Drugs Market

• 14.1. South Korea Hepatocellular Carcinoma Drugs Market Overview
• 14.2. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hepatocellular Carcinoma Drugs Market

• 15.1. Western Europe Hepatocellular Carcinoma Drugs Market Overview
• 15.2. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hepatocellular Carcinoma Drugs Market

• 16.1. UK Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hepatocellular Carcinoma Drugs Market

• 17.1. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hepatocellular Carcinoma Drugs Market

• 18.1. France Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hepatocellular Carcinoma Drugs Market

• 19.1. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hepatocellular Carcinoma Drugs Market

• 20.1. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hepatocellular Carcinoma Drugs Market

• 21.1. Eastern Europe Hepatocellular Carcinoma Drugs Market Overview
• 21.2. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hepatocellular Carcinoma Drugs Market

• 22.1. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hepatocellular Carcinoma Drugs Market

• 23.1. North America Hepatocellular Carcinoma Drugs Market Overview
• 23.2. North America Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hepatocellular Carcinoma Drugs Market

• 24.1. USA Hepatocellular Carcinoma Drugs Market Overview
• 24.2. USA Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hepatocellular Carcinoma Drugs Market

• 25.1. Canada Hepatocellular Carcinoma Drugs Market Overview
• 25.2. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hepatocellular Carcinoma Drugs Market

• 26.1. South America Hepatocellular Carcinoma Drugs Market Overview
• 26.2. South America Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hepatocellular Carcinoma Drugs Market

• 27.1. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hepatocellular Carcinoma Drugs Market

• 28.1. Middle East Hepatocellular Carcinoma Drugs Market Overview
• 28.2. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hepatocellular Carcinoma Drugs Market

• 29.1. Africa Hepatocellular Carcinoma Drugs Market Overview
• 29.2. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hepatocellular Carcinoma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Hepatocellular Carcinoma Drugs Market Competitive Landscape
• 30.2. Hepatocellular Carcinoma Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Amgen Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bayer AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bristol-Myers Squibb Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Celgene Corporation
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Hepatocellular Carcinoma Drugs Market Competitive Benchmarking

32. Global Hepatocellular Carcinoma Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hepatocellular Carcinoma Drugs Market

34. Hepatocellular Carcinoma Drugs Market Future Outlook and Potential Analysis

• 34.1 Hepatocellular Carcinoma Drugs Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Hepatocellular Carcinoma Drugs Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Hepatocellular Carcinoma Drugs Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer